HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.

Abstract
Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In addition, antipsychotic treatments trigger serious side effects that precipitate treatment discontinuation. Here, we show that activation of the trace amine-associated receptor 1 (TAAR1), a modulator of monoaminergic neurotransmission, represents a novel therapeutic option. In rodents, activation of TAAR1 by two novel and pharmacologically distinct compounds, the full agonist RO5256390 and the partial agonist RO5263397, blocks psychostimulant-induced hyperactivity and produces a brain activation pattern reminiscent of the antipsychotic drug olanzapine, suggesting antipsychotic-like properties. TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation. Finally, TAAR1 activation promotes vigilance in rats and shows pro-cognitive and antidepressant-like properties in rodent and primate models. These data suggest that TAAR1 agonists may provide a novel and differentiated treatment of schizophrenia as compared with current medication standards: TAAR1 agonists may improve not only the positive symptoms but also the negative symptoms and cognitive deficits, without causing adverse effects such as motor impairments or weight gain.
AuthorsF G Revel, J-L Moreau, B Pouzet, R Mory, A Bradaia, D Buchy, V Metzler, S Chaboz, K Groebke Zbinden, G Galley, R D Norcross, D Tuerck, A Bruns, S R Morairty, T S Kilduff, T L Wallace, C Risterucci, J G Wettstein, M C Hoener
JournalMolecular psychiatry (Mol Psychiatry) Vol. 18 Issue 5 Pg. 543-56 (May 2013) ISSN: 1476-5578 [Electronic] England
PMID22641180 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antipsychotic Agents
  • Dopamine Uptake Inhibitors
  • Hallucinogens
  • Oxazoles
  • Phenethylamines
  • Pyrrolidinones
  • RO5166017
  • Receptors, G-Protein-Coupled
  • Tritium
  • Benzodiazepines
  • L 687414
  • Cocaine
  • Phencyclidine
  • Haloperidol
  • Olanzapine
  • Trace amine-associated receptor 1
Topics
  • Analysis of Variance
  • Animals
  • Antipsychotic Agents (pharmacology, therapeutic use)
  • Attention (drug effects, physiology)
  • Benzodiazepines (therapeutic use)
  • Body Weight (drug effects)
  • Cocaine (administration & dosage)
  • Conditioning, Operant (drug effects)
  • Depression (drug therapy, etiology)
  • Disease Models, Animal
  • Dopamine Uptake Inhibitors (administration & dosage)
  • Electroencephalography
  • Hallucinogens (toxicity)
  • Haloperidol (adverse effects)
  • Humans
  • Macaca fascicularis
  • Magnetic Resonance Imaging
  • Male
  • Mental Recall (drug effects)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microinjections
  • Motor Activity (drug effects, genetics)
  • Mutation
  • Olanzapine
  • Oocytes
  • Oxazoles (pharmacokinetics)
  • Phencyclidine (toxicity)
  • Phenethylamines (pharmacokinetics)
  • Protein Binding (drug effects, genetics)
  • Pyrrolidinones (administration & dosage)
  • Rats
  • Rats, Wistar
  • Receptors, G-Protein-Coupled (agonists, genetics)
  • Reinforcement, Psychology
  • Schizophrenia (complications, drug therapy, etiology, genetics)
  • Swimming (psychology)
  • Telemetry
  • Tritium (pharmacokinetics)
  • Xenopus

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: